associated need for costly segregation of non-GM products, but the producers of quality-enhanced products actually benefit. …

, or pharmaceutical. Cost structures vary according to the relative importance of segregation and risk management. High …

and market segregation. We represent explicitly the costs of non-GMO segregation and identity preservation (IP) for both … segregation in the European Union (EU). We analyze how the costs of IP are distributed among heterogenous producers, handlers and …

and market segregation. We represent explicitly the costs of non-GMO segregation and identity preservation (IP) for both … segregation in the European Union (EU). We analyze how the costs of IP are distributed among heterogenous producers, handlers and …

The emergence of agricultural biotechnology and the subsequent introduction of genetically modified organisms (GMOs … regulatory response to products of biotechnology. This paper builds on the literature on the regulation of products of … biotechnology by placing the analysis of labeling decisions in a multi-country context. Specifically, the objective of this study is …